{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:59:29Z","timestamp":1792511969991,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jad.2024.07.103","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T17:36:31Z","timestamp":1721237791000},"page":"742-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Comprehensive analysis of adverse events associated with pimavanserin using the FAERS database"],"prefix":"10.1016","volume":"362","author":[{"given":"Jun","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2024.07.103_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.919778","article-title":"Motor-and cognition-related safety of pimavanserin in patients with Parkinson\u2019s disease psychosis[J]","volume":"13","author":"Abler","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jad.2024.07.103_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.prdoa.2022.100143","article-title":"Long-term outcomes with pimavanserin for psychosis in clinical practice[J]","volume":"6","author":"Akbar","year":"2022","journal-title":"Clinical Parkinsonism & Related Disorders"},{"key":"10.1016\/j.jad.2024.07.103_bb0015","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.parkreldis.2020.06.026","article-title":"Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson\u2019s disease psychosis[J]","volume":"77","author":"Ballard","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jad.2024.07.103_bb0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3389\/fphar.2020.00591","article-title":"Identification of a serotonin 2A receptor subtype of schizophrenia spectrum disorders with pimavanserin: the sub-Sero proof-of-concept trial protocol[J]","volume":"11","author":"Baltzersen","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jad.2024.07.103_bb0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation[J]","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"10291","key":"10.1016\/j.jad.2024.07.103_bb0030","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s disease[J]","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jad.2024.07.103_bb0035","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management[J]","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.jad.2024.07.103_bb0040","first-page":"785","article-title":"Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis[J]","volume":"27","author":"Brown","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"1","key":"10.1016\/j.jad.2024.07.103_bb0045","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/ijerph18010198","article-title":"Gender differences and quality of life in Parkinson\u2019s disease[J]","volume":"18","author":"Crispino","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"13","key":"10.1016\/j.jad.2024.07.103_bb0050","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1080\/14656566.2021.1942455","article-title":"Evaluating pimavanserin as a treatment for psychiatric disorders: a pharmacological property in search of an indication[J]","volume":"22","author":"Davis","year":"2021","journal-title":"Expert. Opin. Pharmacother."},{"issue":"13","key":"10.1016\/j.jad.2024.07.103_bb0055","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1080\/14656566.2021.1942455","article-title":"Evaluating pimavanserin as a treatment for psychiatric disorders: a pharmacological property in search of an indication[J]","volume":"22","author":"Davis","year":"2021","journal-title":"Expert. Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.jad.2024.07.103_bb0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system[J]","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am. Stat."},{"issue":"6","key":"10.1016\/j.jad.2024.07.103_bb0065","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports[J]","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jad.2024.07.103_bb0070","author":"Food"},{"issue":"12","key":"10.1016\/j.jad.2024.07.103_bb0075","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s40264-022-01246-4","article-title":"Withdrawal syndrome following discontinuation of 28 antidepressants: pharmacovigilance analysis of 31,688 reports from the WHO spontaneous reporting database[J]","volume":"45","author":"Gastaldon","year":"2022","journal-title":"Drug Saf."},{"key":"10.1016\/j.jad.2024.07.103_bb0080","first-page":"1","article-title":"The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database[J]","author":"Jiang","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2024.07.103_bb0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database[J]","volume":"346","author":"Jiang","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.07.103_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.parkreldis.2020.05.026","article-title":"Treatment of psychosis in Parkinson\u2019s disease and dementia with Lewy bodies: a review[J]","volume":"75","author":"Kyle","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jad.2024.07.103_bb0095","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jad.2024.03.085","article-title":"Multidimensional assessment of adverse events of bupropion: a large-scale data analysis from the FAERS database[J]","volume":"354","author":"Lu","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.07.103_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2024.103968","article-title":"Analysis of the adverse events of Aristada: a real-world study based on FAERS database[J]","volume":"94","author":"Ou","year":"2024","journal-title":"Asian J. Psychiatr."},{"issue":"9","key":"10.1016\/j.jad.2024.07.103_bb0105","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s40265-020-01312-0","article-title":"Treatment of antipsychotic-induced akathisia: role of serotonin 5-HT2a receptor antagonists[J]","volume":"80","author":"Poyurovsky","year":"2020","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.jad.2024.07.103_bb0110","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio[J]","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"10.1016\/j.jad.2024.07.103_bb0115","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/08919887211018280","article-title":"Psychosis in Parkinson\u2019s disease: current treatment options and impact on patients and caregivers[J]","volume":"34","author":"Segal","year":"2021","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"10.1016\/j.jad.2024.07.103_bb0120","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40266-019-00655-y","article-title":"Pimavanserin for psychosis in Parkinson\u2019s disease-related disorders: a retrospective chart review[J]","volume":"36","author":"Sellers","year":"2019","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jad.2024.07.103_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108155","article-title":"Central 5-HT receptors and their function; present and future[J]","volume":"177","author":"Sharp","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2024.07.103_bb0130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/DDDT.S240862","article-title":"Spotlight on pimavanserin tartrate and its therapeutic potential in the treatment of major depressive disorder: the evidence to date[J]","author":"Soogrim","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"issue":"5","key":"10.1016\/j.jad.2024.07.103_bb0135","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.12740\/PP\/OnlineFirst\/115218","article-title":"A case of reversible aphasia-type speech disorders after treatment with quetiapine[J]","volume":"55","author":"Szczygie\u0142-Pilut","year":"2021","journal-title":"Psychiatr. Pol."},{"key":"10.1016\/j.jad.2024.07.103_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105491","article-title":"Establishing a framework for quality of inpatient care for Parkinson\u2019s disease: a study on inpatient medication administration[J]","volume":"113","author":"Yu","year":"2023","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jad.2024.07.103_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2023.103828","article-title":"Adverse events of epidiolex: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database[J]","volume":"90","author":"Zhou","year":"2023","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.jad.2024.07.103_bb0150","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jad.2023.11.076","article-title":"Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database[J]","volume":"347","author":"Zhu","year":"2024","journal-title":"J. Affect. Disord."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724011613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724011613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T12:54:32Z","timestamp":1742216072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724011613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":30,"alternative-id":["S0165032724011613"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.07.103","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive analysis of adverse events associated with pimavanserin using the FAERS database","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.07.103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}